
Page#1
Table of Contents
Item 8. Financial Statements and Supplementary Data.
(a) Financial Statements
The consolidated balance sheet of Merck & Co., Inc. and subsidiaries as of December 31, 2017 and 2016, and
the related consolidated statements of income, of comprehensive income, of equity and of cash flows for each of the
three years in the period ended December 31, 2017, the notes to consolidated financial statements, and the report dated
February 27, 2018 of PricewaterhouseCoopers LLP, independent registered public accounting firm, are as follows:
Consolidated Statement of Income
Merck & Co., Inc. and Subsidiaries
Years Ended December 31
($ in millions except per share amounts)
2017 2016 2015
Sales $ 40,122 $ 39,807 $ 39,498
Costs, Expenses and Other
Materials and production 12,775 13,891 14,934
Marketing and administrative 9,830 9,762 10,313
Research and development 10,208 10,124 6,704
Restructuring costs 776 651 619
Other (income) expense, net 12 720 1,527
33,601 35,148 34,097
Income Before Taxes 6,521 4,659 5,401
Taxes on Income 4,103 718 942
Net Income 2,418 3,941 4,459
Less: Net Income Attributable to Noncontrolling Interests 24 21 17
Net Income Attributable to Merck & Co., Inc. $ 2,394 $ 3,920 $ 4,442
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common
Shareholders $ 0.88 $ 1.42 $ 1.58
Earnings per Common Share Assuming Dilution Attributable to Merck & Co.,
Inc. Common Shareholders $ 0.87 $ 1.41 $ 1.56
Consolidated Statement of Comprehensive Income
Merck & Co., Inc. and Subsidiaries
Years Ended December 31
($ in millions)
2017 2016 2015
Net Income Attributable to Merck & Co., Inc. $ 2,394 $ 3,920 $ 4,442
Other Comprehensive Income (Loss) Net of Taxes:
Net unrealized loss on derivatives, net of reclassifications (446) (66) (126)
Net unrealized loss on investments, net of reclassifications (58) (44) (70)
Benefit plan net gain (loss) and prior service credit (cost), net of amortization 419 (799) 579
Cumulative translation adjustment 401 (169) (208)
316 (1,078) 175
Comprehensive Income Attributable to Merck & Co., Inc. $ 2,710 $ 2,842 $ 4,617
The accompanying notes are an integral part of these consolidated financial statements.
70
Page#2
Table of Contents
Consolidated Balance Sheet
Merck & Co., Inc. and Subsidiaries
December 31
($ in millions except per share amounts)
2017 2016
Assets
Current Assets
Cash and cash equivalents $ 6,092 $ 6,515
Short-term investments 2,406 7,826
Accounts receivable (net of allowance for doubtful accounts of $210 in 2017
6,873 7,018
and $195 in 2016) 
Inventories (excludes inventories of $1,187 in 2017 and $1,117 in 2016
5,096 4,866
classified in Other assets - see Note 7)
Other current assets 4,299 4,389
Total current assets 24,766 30,614
Investments 12,125 11,416
Property, Plant and Equipment (at cost)
Land 365 412
Buildings 11,726 11,439
Machinery, equipment and office furnishings 14,649 14,053
Construction in progress 2,301 1,871
29,041 27,775
Less: accumulated depreciation 16,602 15,749
12,439 12,026
Goodwill 18,284 18,162
Other Intangibles, Net 14,183 17,305
Other Assets 6,075 5,854
$ 87,872 $ 95,377
Liabilities and Equity
Current Liabilities
Loans payable and current portion of long-term debt $ 3,057 $ 568
Trade accounts payable 3,102 2,807
Accrued and other current liabilities 10,427 10,274
Income taxes payable 708 2,239
Dividends payable 1,320 1,316
Total current liabilities 18,614 17,204
Long-Term Debt 21,353 24,274
Deferred Income Taxes 2,219 5,077
Other Noncurrent Liabilities 11,117 8,514
Merck & Co., Inc. Stockholders’ Equity
Common stock, $0.50 par value
Authorized - 6,500,000,000 shares
1,788 1,788
Issued - 3,577,103,522 shares in 2017 and 2016
Other paid-in capital 39,902 39,939
Retained earnings 41,350 44,133
Accumulated other comprehensive loss (4,910) (5,226)
78,130 80,634
Less treasury stock, at cost:
43,794 40,546
880,491,914 shares in 2017 and 828,372,200 shares in 2016
Total Merck & Co., Inc. stockholders’ equity 34,336 40,088
Noncontrolling Interests 233 220
Total equity 34,569 40,308
$ 87,872 $ 95,377
The accompanying notes are an integral part of this consolidated financial statement.
71
Page#3
Table of Contents
Consolidated Statement of Cash Flows
Merck & Co., Inc. and Subsidiaries
Years Ended December 31
($ in millions)
2017 2016 2015
Cash Flows from Operating Activities
Net income $ 2,418 $ 3,941 $ 4,459
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization 4,637 5,441 6,375
Intangible asset impairment charges 646 3,948 162
Provisional charge for one-time transition tax related to the enactment of U.S. tax legislation 5,347 — —
Charge for future payments related to AstraZeneca collaboration license options 500 — —
Charge related to the settlement of worldwide Keytruda patent litigation — 625 —
Foreign currency devaluation related to Venezuela — — 876
Net charge related to the settlement of Vioxx shareholder class action litigation — — 680
Equity income from affiliates (42) (86) (205)
Dividends and distributions from equity method affiliates 2 16 50
Deferred income taxes (2,621) (1,521) (764)
Share-based compensation 312 300 299
Other 269 313 874
Net changes in assets and liabilities:
Accounts receivable 297 (619) (480)
Inventories (145) 206 805
Trade accounts payable 254 278 (37)
Accrued and other current liabilities (922) (2,018) (8)
Income taxes payable (3,291) 124 (266)
Noncurrent liabilities (123) (809) (277)
Other (1,091) 237 (5)
Net Cash Provided by Operating Activities 6,447 10,376 12,538
Cash Flows from Investing Activities
Capital expenditures (1,888) (1,614) (1,283)
Purchases of securities and other investments (10,739) (15,651) (16,681)
Proceeds from sales of securities and other investments 15,664 14,353 20,413
Acquisition of Cubist Pharmaceuticals, Inc., net of cash acquired — — (7,598)
Acquisitions of other businesses, net of cash acquired (396) (780) (146)
Dispositions of businesses, net of cash divested — — 316
Other 38 482 221
Net Cash Provided by (Used in) Investing Activities 2,679 (3,210) (4,758)
Cash Flows from Financing Activities
Net change in short-term borrowings (26) — (1,540)
Payments on debt (1,103) (2,386) (2,906)
Proceeds from issuance of debt — 1,079 7,938
Purchases of treasury stock (4,014) (3,434) (4,186)
Dividends paid to stockholders (5,167) (5,124) (5,117)
Proceeds from exercise of stock options 499 939 485
Other (195) (118) (61)
Net Cash Used in Financing Activities (10,006) (9,044) (5,387)
Effect of Exchange Rate Changes on Cash and Cash Equivalents 457 (131) (1,310)
Net (Decrease) Increase in Cash and Cash Equivalents (423) (2,009) 1,083
Cash and Cash Equivalents at Beginning of Year 6,515 8,524 7,441
Cash and Cash Equivalents at End of Year $ 6,092 $ 6,515 $ 8,524
The accompanying notes are an integral part of this consolidated financial statement.
73